RESUMO
Polyriboinosinic-polyribocytidilic acid (polyI:C) is a synthetic analog that elicits viral-like immune responses in mammals. We have recently found that polyI:C treatment in neonatal mice induced abnormalities of emotional, cognitive, and sensorimotor gating and dysfunction of glutamatergic neurotransmission in adulthood. In this study, we investigated the effect of the NMDA-receptor co-agonist D-serine on polyI:C-induced behavioral abnormalities in mice. Neonatal ICR mice were repeatedly injected with polyI:C for 5 days from postnatal day 2 to 6. At 10 weeks, sensorimotor gating function was analyzed in the prepulse inhibition (PPI) test. Emotional function was analyzed in open field and social interaction tests. Cognitive function was analyzed by novel object recognition tests. D-Serine dose-dependently improved polyI:C-induced impairment of emotional and cognitive behaviors whereas it had no effect on PPI deficit in adults. The ameliorating effects of D-serine were antagonized by pretreatment with an NMDA-receptor antagonist, MK-801. Although the mRNA level of D-amino acid oxidase (DAAO) was increased in the prefrontal cortex and hippocampus of neonatal polyI:C-treated mice in adulthood, no changes were observed in D-serine content and DAAO enzymatic activity. These results suggest that D-serine ameliorates emotional and cognitive impairments of the polyI:C-treated mice through potentiating NMDA receptor activity.
Assuntos
Sintomas Afetivos/prevenção & controle , Viroses do Sistema Nervoso Central/fisiopatologia , Córtex Cerebral/efeitos dos fármacos , Transtornos Cognitivos/prevenção & controle , Modelos Animais de Doenças , Receptores de N-Metil-D-Aspartato/agonistas , Serina/análogos & derivados , Sintomas Afetivos/etiologia , Animais , Animais Recém-Nascidos , Ansiolíticos/antagonistas & inibidores , Ansiolíticos/metabolismo , Ansiolíticos/uso terapêutico , Comportamento Animal/efeitos dos fármacos , Viroses do Sistema Nervoso Central/imunologia , Córtex Cerebral/imunologia , Córtex Cerebral/metabolismo , Transtornos Cognitivos/etiologia , D-Aminoácido Oxidase/genética , D-Aminoácido Oxidase/metabolismo , Comportamento Exploratório/efeitos dos fármacos , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Masculino , Camundongos , Camundongos Endogâmicos ICR , Proteínas do Tecido Nervoso/agonistas , Proteínas do Tecido Nervoso/genética , Proteínas do Tecido Nervoso/metabolismo , Neurônios/efeitos dos fármacos , Neurônios/imunologia , Neurônios/metabolismo , Nootrópicos/antagonistas & inibidores , Nootrópicos/metabolismo , Nootrópicos/uso terapêutico , Distribuição Aleatória , Receptores de N-Metil-D-Aspartato/antagonistas & inibidores , Receptores de N-Metil-D-Aspartato/metabolismo , Serina/antagonistas & inibidores , Serina/metabolismo , Serina/uso terapêutico , Organismos Livres de Patógenos EspecíficosRESUMO
It is established that bicuculline, picrotoxin, and flumazenil (agents blocking different sites of GABA receptor) decrease the anxiolytic effect of piracetam as manifested in the conflict situation test. The most pronounced interaction was observed between piracetam and flumazenyl. On the background of antagonist action, piracetam inhibited the effects of flumazenil (but not those of bicuculline and picrotoxin). Based on these data, it is assumed that the anxiolytic effect of piracetam is mediated to some extent by benzodiazepine site of the GABA-benzodiazepine receptor complex.
Assuntos
Ansiolíticos/farmacologia , Flumazenil/farmacologia , Moduladores GABAérgicos/farmacologia , Antagonistas de Receptores de GABA-A , Nootrópicos/farmacologia , Piracetam/farmacologia , Animais , Ansiolíticos/antagonistas & inibidores , Antagonismo de Drogas , Flumazenil/antagonistas & inibidores , Moduladores GABAérgicos/antagonistas & inibidores , Masculino , Nootrópicos/antagonistas & inibidores , RatosRESUMO
Cannabinoid and endocannabinoid systems have been implicated in several physiological functions including modulation of cognition. In this study we evaluated the effects and interaction between fatty-acid amide hydrolase (FAAH) inhibitor URB597 and CB1 receptor agonist WIN55, 212-2 on memory using object recognition and passive avoidance learning (PAL) tests. Learning and memory impairment was induced by WIN 55, 212-2 administration (1mg/kg, i.p.) 30min before the acquisition trial. URB597 (0.1, 0.3 and 1mg/kg, i.p.) or SR141716A (1mg/kg, i.p.) was injected to rats 10min before WIN 55, 212-2 or URB597 respectively. URB597 (0.3 and 1mg/kg) but not 0.1mg/kg induced higher discrimination index (DI) in object recognition test and enhanced memory acquisition in PAL test. The cognitive enhancing effect of URB597 was blocked by a CB1 receptor antagonist, SR141716A which at this dose alone had no effect on cognition. WIN55, 212-2 caused cognition deficits in both tests. URB597 (0.3 and 1mg/kg) treatment could alleviate the negative influence of WIN 55, 212-2 on cognition and memory. These results indicate URB597 potential to protect against memory deficits induced by cannabinoid. Therefore, in combination with URB597 beneficial effects, this study suggests that URB597 has recognition and acquisition memory enhancing effects. It may also constitute a novel approach for the treatment of cannabinoid induced memory deficits and lead to a better understanding of the brain mechanisms underlying cognition.
Assuntos
Benzamidas/farmacologia , Benzoxazinas/farmacologia , Carbamatos/farmacologia , Aprendizagem/efeitos dos fármacos , Transtornos da Memória/tratamento farmacológico , Morfolinas/farmacologia , Naftalenos/farmacologia , Nootrópicos/farmacologia , Amidoidrolases/antagonistas & inibidores , Animais , Benzamidas/antagonistas & inibidores , Carbamatos/antagonistas & inibidores , Masculino , Transtornos da Memória/induzido quimicamente , Nootrópicos/antagonistas & inibidores , Piperidinas/farmacologia , Pirazóis/farmacologia , Ratos , Ratos Wistar , Receptor CB1 de Canabinoide/antagonistas & inibidores , Retenção Psicológica/efeitos dos fármacos , RimonabantoRESUMO
The cellular events involved in acetyl-L-carnitine (ALCAR) analgesia were investigated in the mouse hot plate test. I.c.v. pretreatment with aODNs against the alpha subunit of G(q) and G(11) proteins prevented the analgesia induced by ALCAR (100 mg kg(-1) s.c. twice daily for 7 days). Administration of the phospholipase C (PLC) inhibitors U-73122 and neomycin, as well as the injection of an aODN complementary to the sequence of PLCbeta(1), antagonized the increase of the pain threshold induced by ALCAR. Pretreatment with U-73343, an analogue of U-73112 inactive on PLC, did not modify ALCAR analgesic effect. In mice undergoing treatment with LiCl, which impairs phosphatidylinositol synthesis, or pretreatment with TMB-8, a blocker of Ca(++) release from intracellular stores, the antinociception induced by ALCAR was dose-dependently antagonized. I.c.v. treatment with heparin, an IP(3) receptor antagonist, prevented the increase of pain threshold induced by the investigated compound, analgesia that was restored by co-administration of D-myo-inositol. On the other hand, i.c.v. pretreatment with the selective protein kinase C (PKC) inhibitors calphostin C and cheleritryne, resulted in a dose-dependent potentiation of ALCAR antinociception. The administration of PKC activators, such as PMA and PDBu, dose-dependently prevented the ALCAR-induced increase of pain threshold. Neither aODNs nor pharmacological treatments produced any behavioral impairment of mice as revealed by the rota-rod and hole board tests. These results indicate that central ALCAR analgesia in mice requires the activation of the PLC-IP(3) pathway. By contrast, the simultaneous activation of PKC may represent a pathway of negative modulation of ALCAR antinociception.
Assuntos
Acetilcarnitina/farmacologia , Analgésicos , Inositol 1,4,5-Trifosfato/fisiologia , Nootrópicos/farmacologia , Fosfolipases Tipo C/fisiologia , Acetilcarnitina/antagonistas & inibidores , Analgésicos/antagonistas & inibidores , Animais , Comportamento Animal/efeitos dos fármacos , Diglicerídeos/farmacologia , Sinergismo Farmacológico , Ativação Enzimática/efeitos dos fármacos , Temperatura Alta , Injeções Intraventriculares , Cloreto de Lítio/farmacologia , Masculino , Camundongos , Nootrópicos/antagonistas & inibidores , Oligonucleotídeos Antissenso/farmacologia , Medição da Dor/efeitos dos fármacos , Equilíbrio Postural , Proteína Quinase C/fisiologia , Tempo de Reação/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacosRESUMO
The effects of nicotine on carbon monoxide (CO)-induced amnesia in mice were investigated using a step-down type passive avoidance task. Mice were exposed to CO 3 times at 1-h intervals, 7 days before the first training and retention test and 24 h after the first training session. Memory deficiency occurred in mice when training commenced more than 3 days after CO exposure (delayed amnesia): the median step-down latency in the retention test of the CO-exposed group was significantly shorter than that of the control group. Administration of (-)-nicotine (15.6 and 31.3 nmol/kg, IP) 15 min before the first training session prolonged the step-down latency in the CO-exposed group, but (+)-nicotine did not. To determine whether this effect of (-)-nicotine was mediated via nicotinic cholinergic receptors, we attempted to block its action using a nicotinic acetylcholine receptor antagonist (mecamylamine). Mecamylamine (1.25 mumol/kg) blocked the effect of (-)-nicotine (31.3 nmol/kg) on delayed amnesia. Administration of (-)-nicotine (15.6-62.5 nmol/kg) immediately after the first training session failed to ameliorate learning ability in the CO-exposed group. These results suggest that (-)-nicotine potentiates the nicotinic cholinergic neuronal system and may potentiate acquisition of memory.
Assuntos
Amnésia/tratamento farmacológico , Intoxicação por Monóxido de Carbono/psicologia , Nicotina/uso terapêutico , Nootrópicos/uso terapêutico , Amnésia/induzido quimicamente , Amnésia/psicologia , Animais , Aprendizagem da Esquiva/efeitos dos fármacos , Eletrochoque , Masculino , Mecamilamina/farmacologia , Memória/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos , Atividade Motora/efeitos dos fármacos , Nicotina/antagonistas & inibidores , Antagonistas Nicotínicos , Nootrópicos/antagonistas & inibidores , Receptores Nicotínicos/efeitos dos fármacosRESUMO
The effect of intracerebrovenricularly (i.c.v.) injected choline on blood pressure was investigated in rats made hypotensive by blocking peripheral alpha-adrenoceptors or autonomic ganglionic transmission. Choline (50-150 micrograms; i.c.v.) increased blood pressure in a dose-dependent manner and 150 micrograms of choline restored blood pressure to the resting level. The pressor response to choline was associated with an increase in plasma vasopressin levels. Pretreatment with mecamylamine (50 micrograms; i.c.v.), but not atropine (10 micrograms; i.c.v.), blocked both the pressor and vasopressin responses to i.c.v. choline. The vasopressin receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylene-propionyl1,O-Me-T ry2,Arg8] vasopressin (10 micrograms/kg; i.v.), given 5 min after i.c.v. choline (150 micrograms), abolished the pressor effect of choline and blood pressure returned to the pre-choline levels. It is concluded that the precursor of acetylcholine, choline, can increase blood pressure and reverse hypotension in alpha-adrenoceptor or ganglionic transmission blocked rats, by increasing plasma vasopressin.
Assuntos
Colina/farmacologia , Nootrópicos/farmacologia , Vasoconstritores/sangue , Vasopressinas/sangue , Antagonistas Adrenérgicos alfa/farmacologia , Antagonistas Adrenérgicos beta/farmacologia , Análise de Variância , Animais , Pressão Sanguínea/efeitos dos fármacos , Colina/antagonistas & inibidores , Relação Dose-Resposta a Droga , Bloqueadores Ganglionares/farmacologia , Frequência Cardíaca/efeitos dos fármacos , Hexametônio/farmacologia , Hipotensão/induzido quimicamente , Hipotensão/tratamento farmacológico , Masculino , Mecamilamina/farmacologia , Antagonistas Nicotínicos/farmacologia , Nootrópicos/antagonistas & inibidores , Fentolamina/farmacologia , Propranolol/farmacologia , Ratos , Vasoconstritores/farmacologia , Vasopressinas/farmacologiaRESUMO
The present experiment examined whether p-chloroamphetamine (PCA), a serotonergic releasing/depleting agent, would block the memory-enhancing effect of physostigmine in rats with N-methyl-D-aspartic acid (NMDA)-induced unilateral lesions of the nucleus basalis of Meynert (uni-nbM). Six groups of subjects with uni-nbM lesions in addition to an isolated sham-operated control group were included. Subjects were trained and tested 72 h later on a one-trial passive avoidance task. Thirty minutes before training, rats with uni-nbM lesions were injected with either 1.0 or 5.0 mg/kg PCA or saline. Immediately after training, approximately half the subjects in each group were injected with either saline or 0.06 mg/kg physostigmine. Animals in the sham group received saline injections. Saline-injected animals with uni-nbM lesions performed poorly at test, a deficit that was reversed with physostigmine. Pretraining injections of PCA blocked physostigmine's memory-enhancing effect, although motor impairment during training may have contributed to decrements in test performance in animals injected with 5.0 mg/kg. Subjects were killed about 10 days later and their frontal cortices examined for choline acetyltransferase (ChAT). Results from the neurochemical analysis revealed that the lesion decreased ChAT levels and that the injection of 1.0 mg/kg PCA exaggerated this lesion-induced depletion. Implications for the interaction between acetylcholine and serotonin are discussed.
Assuntos
Núcleo Basal de Meynert/efeitos dos fármacos , Memória/efeitos dos fármacos , Nootrópicos/antagonistas & inibidores , Fisostigmina/antagonistas & inibidores , p-Cloroanfetamina/farmacologia , Animais , Aprendizagem da Esquiva/efeitos dos fármacos , Aprendizagem da Esquiva/fisiologia , Núcleo Basal de Meynert/fisiologia , Masculino , Memória/fisiologia , Nootrópicos/farmacologia , Fisostigmina/farmacologia , Ratos , Ratos Sprague-DawleyRESUMO
Studies were carried out on the effects of piracetam (4-20 mM) on the electrical activity of identified neurons in the isolated central nervous system of the pond snail in conditions of single-electrode intracellular stimulation and recording. Piracetam-induced changes were seen in 60-70% of the neurons studied. Different parameters showed different sensitivities to piracetam: the most frequent changes were in the action potential generation threshold, the slope and shape of the steady-state voltage-current characteristics of neuron membranes, and the appearance of piracetam-induced transmembrane ion currents. Nifedipine and cadmium ions, both of which are calcium channel blockers, generally reversed or weakened the effects of piracetam on the changes seen in test cells. This indicates that the effects of piracetam result from its action on calcium channels; selective changes in calcium channels may determine which piracetam-induced effects appear at the cellular level. It is hypothesized that the piracetam-sensitive cellular plasticity mechanisms may make a significant contribution to its nootropic action at the behavioral level.
Assuntos
Lymnaea/fisiologia , Neurônios/efeitos dos fármacos , Nootrópicos/farmacologia , Piracetam/farmacologia , Animais , Cádmio/farmacologia , Bloqueadores dos Canais de Cálcio/farmacologia , Eletrofisiologia , Gânglios dos Invertebrados/citologia , Gânglios dos Invertebrados/fisiologia , Técnicas In Vitro , Potenciais da Membrana/efeitos dos fármacos , Potenciais da Membrana/fisiologia , Nifedipino/farmacologia , Nootrópicos/antagonistas & inibidores , Lobo Parietal/citologia , Lobo Parietal/efeitos dos fármacos , Técnicas de Patch-Clamp , Piracetam/antagonistas & inibidoresRESUMO
Epigallocatechin gallate (EGCG) is a major polyphenol in green tea with beneficial effects on the impairment in learning and memory. Autophagy is a cellular process that protects neurons from stressful conditions. The present study was designed to investigate whether EGCG can rescue chronic unpredictable mild stress (CUMS)-induced cognitive impairment in rats and whether its protective effect involves improvement of autophagic flux. As expected, our results showed that CUMS significantly impaired memory performance and inhibited autophagic flux as indicated by elevated LC3-II and p62 protein levels. At the same time, we observed an increased neuronal loss and activated mammalian target of rapamycin (mTOR)/p70 ribosomal protein S6 kinase (p70S6k) signaling in the CA1 regions. Interestingly, chronic treatment with EGCG (25 mg/kg, i.p.) significantly improved those behavioral alterations, attenuated histopathological abnormalities in hippocampal CA1 regions, reduced amyloid beta1-42 (Aß1-42) levels, and restored autophagic flux. However, blocking autophagic flux with chloroquine, an inhibitor of autophagic flux, reversed these effects of EGCG. Taken together, these findings suggest that the impaired autophagy in CA1 regions of CUMS rats may contribute to learning and memory impairment. Therefore, we conclude that EGCG attenuation of CUMS-induced learning and memory impairment may be through rescuing autophagic flux.
Assuntos
Catequina/análogos & derivados , Disfunção Cognitiva/tratamento farmacológico , Aprendizagem em Labirinto/efeitos dos fármacos , Memória/efeitos dos fármacos , Nootrópicos/farmacologia , Estresse Psicológico/tratamento farmacológico , Peptídeos beta-Amiloides/genética , Peptídeos beta-Amiloides/metabolismo , Animais , Autoantígenos/genética , Autoantígenos/metabolismo , Autofagia/efeitos dos fármacos , Região CA1 Hipocampal/efeitos dos fármacos , Região CA1 Hipocampal/metabolismo , Região CA1 Hipocampal/patologia , Catequina/antagonistas & inibidores , Catequina/farmacologia , Cloroquina/farmacologia , Doença Crônica , Disfunção Cognitiva/etiologia , Disfunção Cognitiva/genética , Disfunção Cognitiva/fisiopatologia , Regulação da Expressão Gênica , Masculino , Proteínas Associadas aos Microtúbulos/genética , Proteínas Associadas aos Microtúbulos/metabolismo , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Neurônios/patologia , Nootrópicos/antagonistas & inibidores , Fragmentos de Peptídeos/genética , Fragmentos de Peptídeos/metabolismo , Ratos , Ratos Wistar , Proteínas Quinases S6 Ribossômicas 70-kDa/genética , Proteínas Quinases S6 Ribossômicas 70-kDa/metabolismo , Transdução de Sinais , Estresse Psicológico/complicações , Estresse Psicológico/genética , Estresse Psicológico/fisiopatologia , Serina-Treonina Quinases TOR/genética , Serina-Treonina Quinases TOR/metabolismoRESUMO
BACKGROUND AND PURPOSE: Here, we describe the in vitro and in vivo effects of (4R,5S)-2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide (E1R), a novel positive allosteric modulator of sigma-1 receptors. EXPERIMENTAL APPROACH: E1R was tested for sigma receptor binding activity in a [³H](+)-pentazocine assay, in bradykinin (BK)-induced intracellular Ca²âº concentration ([Ca²âº](i)) assays and in an electrically stimulated rat vas deferens model. E1R's effects on cognitive function were tested using passive avoidance (PA) and Y-maze tests in mice. A selective sigma-1 receptor antagonist (NE-100), was used to study the involvement of the sigma-1 receptor in the effects of E1R. The open-field test was used to detect the effects of E1R on locomotion. KEY RESULTS: Pretreatment with E1R enhanced the selective sigma-1 receptor agonist PRE-084's stimulating effect during a model study employing electrically stimulated rat vasa deferentia and an assay measuring the BK-induced [Ca²âº](i) increase. Pretreatment with E1R facilitated PA retention in a dose-related manner. Furthermore, E1R alleviated the scopolamine-induced cognitive impairment during the PA and Y-maze tests in mice. The in vivo and in vitro effects of E1R were blocked by treatment with the selective sigma-1 receptor antagonist NE-100. E1R did not affect locomotor activity. CONCLUSION AND IMPLICATIONS: E1R is a novel 4,5-disubstituted derivative of piracetam that enhances cognition and demonstrates efficacy against scopolamine-induced cholinergic dysfunction in mice. These effects are attributed to its positive modulatory action on the sigma-1 receptor and this activity may be relevant when developing new drugs for treating cognitive symptoms related to neurodegenerative diseases.
Assuntos
Acetamidas/uso terapêutico , Amnésia/prevenção & controle , Cognição/efeitos dos fármacos , Modelos Animais de Doenças , Fármacos Neuroprotetores/uso terapêutico , Nootrópicos/uso terapêutico , Piracetam/análogos & derivados , Pirrolidinonas/uso terapêutico , Receptores sigma/agonistas , Acetamidas/efeitos adversos , Acetamidas/antagonistas & inibidores , Acetamidas/farmacologia , Regulação Alostérica , Amnésia/metabolismo , Animais , Comportamento Animal/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Sinalização do Cálcio/efeitos dos fármacos , Linhagem Celular , Neurônios Colinérgicos/efeitos dos fármacos , Neurônios Colinérgicos/metabolismo , Sinergismo Farmacológico , Técnicas In Vitro , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos ICR , Atividade Motora/efeitos dos fármacos , Proteínas do Tecido Nervoso/agonistas , Proteínas do Tecido Nervoso/antagonistas & inibidores , Proteínas do Tecido Nervoso/metabolismo , Fármacos Neuroprotetores/efeitos adversos , Fármacos Neuroprotetores/antagonistas & inibidores , Fármacos Neuroprotetores/farmacologia , Nootrópicos/efeitos adversos , Nootrópicos/antagonistas & inibidores , Nootrópicos/farmacologia , Piracetam/antagonistas & inibidores , Piracetam/farmacologia , Piracetam/uso terapêutico , Pirrolidinonas/efeitos adversos , Pirrolidinonas/antagonistas & inibidores , Pirrolidinonas/farmacologia , Ratos , Ratos Wistar , Receptores sigma/antagonistas & inibidores , Receptores sigma/metabolismo , Ducto Deferente/efeitos dos fármacos , Ducto Deferente/metabolismo , Receptor Sigma-1RESUMO
Angiotensin IV (Val(1)-Tyr(2)-Ile(3)-His(4)-Pro(5)-Phe(6)) has demonstrated potential cognitive-enhancing effects. The present investigation assessed and characterized: (1) dose-dependency of angiotensin IV's cognitive enhancement in a C57BL/6J mouse model of novel object recognition, (2) the time-course for these effects, (3) the identity of residues in the hexapeptide important to these effects and (4) the necessity of actions at angiotensin IV receptors for procognitive activity. Assessment of C57BL/6J mice in a novel object recognition task demonstrated that prior administration of angiotensin IV (0.1, 1.0, or 10.0, but not 0.01 nmol, i.c.v.) significantly enhanced novel object recognition in a dose-dependent manner. These effects were time dependent, with improved novel object recognition observed when angiotensin IV (0.1 nmol, i.c.v.) was administered 10 or 20, but not 30 min prior to the onset of the novel object recognition testing. An alanine scan of the angiotensin IV peptide revealed that replacement of the Val(1), Ile(3), His(4), or Phe(6) residues with Ala attenuated peptide-induced improvements in novel object recognition, whereas Tyr(2) or Pro(5) replacement did not significantly affect performance. Administration of the angiotensin IV receptor antagonist, divalinal-Ang IV (20 nmol, i.c.v.), reduced (but did not abolish) novel object recognition; however, this antagonist completely blocked the procognitive effects of angiotensin IV (0.1 nmol, i.c.v.) in this task. Rotorod testing demonstrated no locomotor effects with any angiotensin IV or divalinal-Ang IV dose tested. These data demonstrate that angiotensin IV produces a rapid enhancement of associative learning and memory performance in a mouse model that was dependent on the angiotensin IV receptor.
Assuntos
Angiotensina II/análogos & derivados , Nootrópicos/farmacologia , Reconhecimento Psicológico/efeitos dos fármacos , Alanina/química , Angiotensina II/administração & dosagem , Angiotensina II/síntese química , Angiotensina II/farmacologia , Antagonistas de Receptores de Angiotensina/farmacologia , Animais , Relação Dose-Resposta a Droga , Infusões Intraventriculares , Masculino , Camundongos , Atividade Motora/efeitos dos fármacos , Nootrópicos/administração & dosagem , Nootrópicos/antagonistas & inibidores , Fatores de TempoRESUMO
7,8-Dihydroxyflavone (7,8 DHF) is a new recently identified TrkB receptor agonist, which possesses a potent neurotrophic activity and shares many physiological properties with the neurotrophin "Brain Derived Neurotrophic Factor" (BDNF). However, its precise mechanism of action at the cellular level has not been clarified yet. In the present study we explored the effects of this agent on synaptic and intrinsic neuronal properties by performing whole-cell patch clamp recordings from layer 2/3 pyramidal neurons. Incubation of acute cortical slices with 7,8-DHF (20 µM) for 30 min caused a selective reduction in the strength of GABAergic inhibition. The amplitude of evoked inhibitory postsynaptic currents (eIPSCs) was significantly reduced to 48.2±8.9% of the control level. This might be a result of decreased presynaptic γ-aminobutyric acid (GABA) release, as suggested by the reduced frequency of miniature inhibitory postsynaptic currents (mIPSCs) (control: 10.7±0.7 Hz, 7,8 DHF: 7.9±0.6 Hz) and increased Paired-Pulse Ratio (PPR) (50±8.9%). Conversely, the glutamatergic transmission was unaffected. Moreover, 7,8-DHF was able to alter the intrinsic neuronal excitability, by significantly increasing spike frequency and input resistance (control: 243.75±23.4 MΩ, 7,8 DHF: 338.5±25.1 MΩ). Remarkably, all reported effects were abolished in presence of the TrkB receptor antagonist K252a indicating a direct involvement of TrkB receptors in the action of 7,8-DHF. These data indicate that 7,8-DHF might be one promising candidate for the development of a new class of drugs called "BDNF mimetics" for the future treatment of cognitive disorders and neurodegenerative diseases.
Assuntos
Flavonas/farmacologia , Neurônios GABAérgicos/efeitos dos fármacos , Proteínas do Tecido Nervoso/agonistas , Fármacos Neuroprotetores/farmacologia , Receptor trkB/agonistas , Transmissão Sináptica/efeitos dos fármacos , Córtex Visual/efeitos dos fármacos , Animais , Células Cultivadas , Impedância Elétrica , Potenciais Evocados Visuais/efeitos dos fármacos , Flavonas/antagonistas & inibidores , Antagonistas de Receptores de GABA-A/farmacologia , Neurônios GABAérgicos/metabolismo , Técnicas In Vitro , Cinética , Camundongos , Camundongos Endogâmicos C57BL , Proteínas do Tecido Nervoso/antagonistas & inibidores , Proteínas do Tecido Nervoso/metabolismo , Inibição Neural/efeitos dos fármacos , Fármacos Neuroprotetores/antagonistas & inibidores , Nootrópicos/antagonistas & inibidores , Nootrópicos/farmacologia , Inibidores de Proteínas Quinases/farmacologia , Células Piramidais/citologia , Células Piramidais/efeitos dos fármacos , Células Piramidais/metabolismo , Receptor trkB/antagonistas & inibidores , Receptor trkB/metabolismo , Receptores de GABA-A/química , Receptores de GABA-A/metabolismo , Córtex Visual/metabolismoRESUMO
The histamine H4 receptor (H4R) is expressed primarily on cells involved in inflammation and immune responses. Recently, it has been reported the functional expression of H4R within neurons of the central nervous system, but their role has been poorly understood. The present study aimed to elucidate the physiopathological role of cerebral H4R in animal models by the intracerebroventricular administration of the H4R agonist VUF 8430 (20-40 µg per mouse). Selectivity of results was confirmed by the prevention of the effects produced by the H4R antagonist JNJ 10191584 (3-9 mg/kg p.o.). Neuronal H4R activation induced acute thermal antinociception, indicating that neuronal histamine H4R might be involved in the production of antinociception in the absence of an inflammatory process. An anxiolytic-like effect of intensity comparable to that exerted by diazepam, used as reference drug, was produced in the light-dark box test. VUF 8430 reversed the scopolamine-induced amnesia in the passive avoidance test and showed anorexant activity in food deprived mice. Conversely, the H4R activation did not modify the immobility time in the tail suspension test. Rotarod performance test was employed to demonstrate that the effects observed following the administration of VUF 8430 and JNJ 10191584 were not due to impaired motor function of animals. Furthermore, both compounds did not alter spontaneous mobility and exploratory activity in the hole board test. These results show the antinociceptive, antiamnesic, anxiolytic and anorexant effects induced by neuronal H4R agonism, suggesting that H4 modulators may have broader utility further the control of inflammatory and immune processes.
Assuntos
Analgésicos/uso terapêutico , Ansiolíticos/uso terapêutico , Depressores do Apetite/uso terapêutico , Sistema Nervoso Central/efeitos dos fármacos , Agonistas dos Receptores Histamínicos/uso terapêutico , Nootrópicos/uso terapêutico , Receptores Acoplados a Proteínas G/agonistas , Analgésicos/agonistas , Analgésicos/antagonistas & inibidores , Animais , Ansiolíticos/agonistas , Ansiolíticos/antagonistas & inibidores , Antidepressivos/uso terapêutico , Depressores do Apetite/química , Comportamento Animal/efeitos dos fármacos , Benzimidazóis/administração & dosagem , Benzimidazóis/farmacologia , Sistema Nervoso Central/metabolismo , Relação Dose-Resposta a Droga , Guanidinas/administração & dosagem , Guanidinas/farmacologia , Agonistas dos Receptores Histamínicos/administração & dosagem , Agonistas dos Receptores Histamínicos/química , Agonistas dos Receptores Histamínicos/farmacologia , Antagonistas dos Receptores Histamínicos/administração & dosagem , Antagonistas dos Receptores Histamínicos/farmacologia , Masculino , Camundongos , Atividade Motora/efeitos dos fármacos , Proteínas do Tecido Nervoso/agonistas , Proteínas do Tecido Nervoso/antagonistas & inibidores , Proteínas do Tecido Nervoso/metabolismo , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Nootrópicos/agonistas , Nootrópicos/antagonistas & inibidores , Distribuição Aleatória , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Receptores Acoplados a Proteínas G/metabolismo , Receptores Histamínicos/metabolismo , Receptores Histamínicos H4 , Tioureia/administração & dosagem , Tioureia/análogos & derivados , Tioureia/farmacologiaRESUMO
The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHßE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (ERK 1/2). Young male rats that were implanted bilaterally with cannulae were submitted to memory extinction tests sessions, and their hippocampi were dissected for biochemical assays. The extinction of fear memory was significantly improved by both nicotine and its metabolite. Cotinine significantly increased LPO, while nicotine significantly decreased it. Antioxidant capacity was increased by all treatments. Our results showed that cotinine, unlike nicotine, may increase oxidative stress in the hippocampus, but this increase depends upon the dose used and happens without causing corresponding impairments in cognitive function. Cotinine also increased the phosphorylation of ERK 1/2 in a similar fashion as nicotine. Considering these results, it is plausible to wonder to what extent nicotine-attributed effects are really due to the actions of this alkaloid and whether they could be due instead to cotinine or to cotinine-nicotine interactions within the brain.
Assuntos
Cotinina/farmacologia , Extinção Psicológica/efeitos dos fármacos , Hipocampo/efeitos dos fármacos , Memória/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Agonistas Nicotínicos/farmacologia , Nootrópicos/farmacologia , Animais , Antioxidantes/metabolismo , Comportamento Animal/efeitos dos fármacos , Cotinina/administração & dosagem , Cotinina/efeitos adversos , Cotinina/antagonistas & inibidores , Relação Dose-Resposta a Droga , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Hipocampo/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Neurônios/metabolismo , Nicotina/efeitos adversos , Nicotina/antagonistas & inibidores , Nicotina/farmacologia , Agonistas Nicotínicos/administração & dosagem , Agonistas Nicotínicos/efeitos adversos , Agonistas Nicotínicos/química , Antagonistas Nicotínicos/farmacologia , Nootrópicos/administração & dosagem , Nootrópicos/efeitos adversos , Nootrópicos/antagonistas & inibidores , Fosforilação/efeitos dos fármacos , Processamento de Proteína Pós-Traducional/efeitos dos fármacos , Ratos , Ratos WistarRESUMO
Low doses of oxytocin enhance learning and memory in animal models. Angiotensin IV inhibits cysteine aminopeptidase, also known as insulin-regulated aminopeptidase and oxytocinase, and enhances memory in animals. The mechanism of this effect of angiotensin IV is unknown. This study explored the role of oxytocin in the cognitive effects of angiotensin IV with physostigmine as a control and used isolated smooth muscle to assess the pharmacological selectivity of the observed antagonism. Using novel object recognition in male mice, the effects of angiotensin IV (4.7 µg/kg), oxytocin (0.1 ng/kg) or physostigmine (200 µg/kg) administered subcutaneously immediately after the second training trial, were assessed in the presence and absence of 10 µg/kg ß-mercapto-ß-ß-cyclopenta-methylenepropionyl; O-Me-Tyr², Orn8-oxytocin, an oxytocin antagonist; n=8 in all cases. The effects of the antagonist on angiotensin IV, oxytocin and acetylcholine-induced contractions of rat isolated uterus were also determined. Oxytocin, angiotensin IV and physostigmine significantly enhanced consolidation of learning (P=0.04, 0.004 and 0.008 respectively), and there were no significant effects on locomotor activity. The oxytocin antagonist similarly not only significantly improved novel object recognition (P=0.03) but also significantly increased locomotor activity (P=0.04). In the learning paradigm the oxytocin antagonist prevented the effects of oxytocin, angiotensin IV and physostigmine but in the uterus, contractions induced by angiotensin IV and acetylcholine were unaffected whilst effects of oxytocin were significantly reduced. These results suggest that the pro-cognitive effects of angiotensin IV may be mediated by accumulation of endogenous oxytocin although the mechanisms underlying the observed interaction between the oxytocin antagonist and physostigmine are unclear.
Assuntos
Angiotensinas/farmacologia , Cognição/efeitos dos fármacos , Cistinil Aminopeptidase/antagonistas & inibidores , Antagonistas de Hormônios/farmacologia , Nootrópicos/farmacologia , Ocitocina/antagonistas & inibidores , Fisostigmina/farmacologia , Animais , Comportamento Animal/efeitos dos fármacos , Feminino , Técnicas In Vitro , Aprendizagem/efeitos dos fármacos , Masculino , Memória/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos C57BL , Atividade Motora/efeitos dos fármacos , Contração Muscular/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Miométrio/efeitos dos fármacos , Nootrópicos/antagonistas & inibidores , Ocitocina/farmacologia , Inibidores de Proteases/química , Inibidores de Proteases/metabolismo , Ratos , Ratos Sprague-DawleyRESUMO
Cannabinoids have been shown to exert neuroprotective effects in a plethora of neurodegenerative conditions. Over the past decade, some studies demonstrate that cannabinoids can interact with nuclear peroxisome proliferator-activated receptors (PPARs). We investigated protective properties of WIN55212-2 (WIN, a non-selective cannabinoid receptor agonist) in beta-amyloid (Aß)-induced neurodegeneration in rat hippocampus and possible involvement of PPAR-gamma (PPAR-γ). Aß (1-42) was injected into the hippocampus of male rats. Animals were administered by intracerebroventricular rout the following treatments on days 1, 3, 5, 7: vehicle, WIN, GW9662 (selective PPAR-γ antagonist) plus WIN, AM251 (selective CB1 receptor antagonist) plus WIN, SR144528 (selective CB2 receptor antagonist) plus WIN, each of antagonists alone. Injection of Aß-induced spatial memory impairment and a dramatic rise in hippocampal TNF-α, active caspase 3, nuclear NF-kB levels and TUNEL-positive neurons. WIN administration significantly improved memory function and diminished the elevated levels of these markers, while antagonizing either CB1 or CB2 receptor subtype partially attenuated the protective effects. Intriguingly, WIN significantly increased PPAR-γ level and transcriptional activity, the latter being partially inhibited with AM251 but not with SR144528. The enhancing effect on PPAR-γ pathway was crucial to WIN-induced neuroprotection since GW9662 partially reversed the beneficial actions of WIN. Co-administration of the three antagonists led to the complete abrogation of WIN effects. Our findings indicate that WIN exerts neuroprotective and anti-inflammatory actions against Aß damage through both CB1 and CB2 receptors. Of great note, both direct and CB1-mediated increase in PPAR-γ signaling also contributes to WIN-induced neuroprotection.
Assuntos
Doença de Alzheimer/tratamento farmacológico , Anti-Inflamatórios não Esteroides/uso terapêutico , Benzoxazinas/uso terapêutico , Hipocampo/efeitos dos fármacos , Morfolinas/uso terapêutico , Naftalenos/uso terapêutico , PPAR gama/agonistas , Receptores de Canabinoides/metabolismo , Transdução de Sinais/efeitos dos fármacos , Doença de Alzheimer/imunologia , Doença de Alzheimer/metabolismo , Doença de Alzheimer/patologia , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/antagonistas & inibidores , Benzoxazinas/administração & dosagem , Benzoxazinas/antagonistas & inibidores , Agonistas de Receptores de Canabinoides/administração & dosagem , Agonistas de Receptores de Canabinoides/química , Agonistas de Receptores de Canabinoides/uso terapêutico , Antagonistas de Receptores de Canabinoides/farmacologia , Modelos Animais de Doenças , Hipocampo/imunologia , Hipocampo/metabolismo , Hipocampo/patologia , Injeções Intraventriculares , Masculino , Morfolinas/administração & dosagem , Morfolinas/antagonistas & inibidores , Naftalenos/administração & dosagem , Naftalenos/antagonistas & inibidores , Proteínas do Tecido Nervoso/agonistas , Proteínas do Tecido Nervoso/antagonistas & inibidores , Proteínas do Tecido Nervoso/metabolismo , Neuroglia/efeitos dos fármacos , Neuroglia/imunologia , Neuroglia/metabolismo , Neuroglia/patologia , Neurônios/efeitos dos fármacos , Neurônios/imunologia , Neurônios/metabolismo , Neurônios/patologia , Nootrópicos/administração & dosagem , Nootrópicos/antagonistas & inibidores , Nootrópicos/uso terapêutico , PPAR gama/antagonistas & inibidores , PPAR gama/metabolismo , Distribuição Aleatória , Ratos , Ratos Wistar , Receptor CB1 de Canabinoide/agonistas , Receptor CB1 de Canabinoide/antagonistas & inibidores , Receptor CB1 de Canabinoide/metabolismo , Receptor CB2 de Canabinoide/agonistas , Receptor CB2 de Canabinoide/antagonistas & inibidores , Receptor CB2 de Canabinoide/metabolismo , Receptores de Canabinoides/químicaRESUMO
Nefiracetam is a new pyrrolidone nootropic drug being developed for the treatment of Alzheimer's type and post-stroke vascular-type dementia. In the brain of Alzheimer's disease patients, down-regulation of both cholinergic and glutamatergic systems has been found and is thought to play an important role in impairment of cognition, learning and memory. We have previously shown that the activity of neuronal nicotinic acetylcholine receptors is potently augmented by nefiracetam. The present study was undertaken to elucidate the mechanism of action of nefiracetam on glutamatergic receptors. Currents were recorded from rat cortical neurons in long-term primary culture using the whole-cell patch-clamp technique at a holding potential of -70 mV in Mg2+-free solutions. N-Methyl-D-aspartate (NMDA)-evoked currents were greatly and reversibly potentiated by bath application of nefiracetam resulting in a bell-shaped dose-response curve. The minimum effective nefiracetam concentration was 1 nM, and the maximum potentiation to 170% of the control was produced at 10 nM. Nefiracetam potentiation occurred at high NMDA concentrations that evoked the saturated response, and in a manner independent of NMDA concentrations ranging from 3 to 1,000 microM. Glycine at 3 microM potentiated NMDA currents but this effect was attenuated with an increasing concentration of nefiracetam from 1 to 10,000 nM. 7-Chlorokynurenic acid at 1 microM prevented nefiracetam from potentiating NMDA currents. Nefiracetam at 10 nM shifted the dose-response relationship for the 7-chlorokynurenic acid inhibition of NMDA currents in the direction of higher concentrations. Alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid- and kainate-induced currents were not significantly affected by application of 10 nM nefiracetam. It was concluded that nefiracetam potentiated NMDA currents through interactions with the glycine binding site of the NMDA receptor.